RFCA
ANTH

R&F Capital Advisors’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

R&F Capital Advisors’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-21,401
Closed -$111K – 891
2016
Q4 		$111K Buy
+21,401
New +$370K 0.04% 448

Other funds holding ANTH

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

R&F Capital Advisors's ANTH Position: Q1 2017 in Review

R&F Capital Advisors sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q1 2017, closing a stake of 21,401 shares — an estimated $111K sold.

R&F Capital Advisors first reported a position in ANTH in Q4 2016 and held it in 1 quarter. The position peaked at $111K in Q4 2016. 60 funds tracked by Wall St. Rank hold ANTH as of Q1 2017.

  • R&F Capital Advisors reported no remaining Anthera Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • R&F Capital Advisors sold 21,401 Anthera Pharmaceuticals, Inc. shares in Q1 2017, an estimated $111K.
  • R&F Capital Advisors first reported a position in Anthera Pharmaceuticals, Inc. in Q4 2016 and held it in 1 quarter.
  • R&F Capital Advisors's Anthera Pharmaceuticals, Inc. position peaked at $111K in Q4 2016.
  • 60 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.